Activbiotics Pharma, LLC

Activbiotics, Inc.

Innate Biotherapeutics, LLC

James Michael Siedlecki

John Henry Van Duzer

Xiang Y Yu

William Bert Geiss

Douglas Gregory Stafford

Arthur F Michaelis

Yingfei Yang

Joseph Raker

Gabriel Oscar Reznik

Hua Miao

Ifat Rubin-Bejerano

John James Kane

Arthur F Kluge

Eric Steven Furfine

Zuzana Dostalova

Isabelle Sansal-Castellano

The present invention encompasses embodiments in which a therapeutic antibody is conjugated to β-1,6-glucan oligomers. Thus, the present invention includes, among other things, compositions including a therapeutic antibody conjugated to one or more β-1,6-glucan oligomers. The present invention further includes, among other things, methods of making and/or using such β-1,6-glucan conjugates. In certain embodiments, a β-1,6-glucan conjugate of the present invention is useful as a therapeutic or in a method of therapy.

ß-1,6-glucan therapeutic antibody conjugates

This invention relates to modifications of &#x3b2;-1,6-D-glucans, e.g., structures according to Formula (I), and the ability of these compositions to modulate an immune response. 

Immunomodulating beta-1,6-D-glucans

The present invention features rifamycin analogs and methods of using these compounds to treat a variety of microbial infections.

Rifamycin analogs and uses thereof

The present invention features rifamycin analogs that can be used as therapeutics for treating or preventing a variety of microbial infections. In one form, the analogs are acetylated at the 25-position, as is rifamycin. In another form, the analogs are deacetylated at the 25-position. In yet other forms, benzoxazinorifamycin, benzthiazinorifamycin, and benzdiazinorifamycin analogs are derivatized at various positions of the benzene ring, including 3'-hydroxy analogs, and/or various fused ring systems with the benzene ring at the 4&#x2032;,5&#x2032; or 5&#x2032;,6&#x2032; positions.

The present invention features rifamycin analogs that can be used as therapeutics for treating or preventing a variety of microbial infections. In one form, the analogs are acetylated at the 25-position, as is rifamycin. In another form, the analogs are deacetylated at the 25-position. In yet other forms, benzoxazinorifamycin, benzthiazinorifamycin, and benzdiazinorifamycin analogs are derivatized at various positions of the benzene ring, including 3'-hydroxy analogs, 5&#x2032;-halo and/or alkoxy analogs, and various 4&#x2032;- and/or 6&#x2032;-substituents that incorporate a cyclic amine moiety.

The present invention features rifamycin analogs that can be used as therapeutics for treating or preventing a variety of microbial infections. In one form, the analogs are acetylated at the 25-position, as is rifamycin. In another form, the analogs are deacetylated at the 25-position. In yet other forms, benzoxazinorifamycin, benzthiazinorifamycin, and benzdiazinorifamycin analogs are derivatized at various positions of the benzene ring, including 3'-hydroxy analogs, 4&#x2032;- and/or 6&#x2032; halo and/or alkoxy analogs, and various 5&#x2032; substituents that incorporate a cyclic amine moiety.

Growing community of inventors

Burlington, MA, United States of America

James Michael Siedlecki